In an experimental study, the effect of sulforapne (25 mg/kg and 50 mg/kg), which reduces NO release, on neuroinflammation and hyperphosphorylated Tau protein through regulation of the PI3K/Akt/GSK-3 β pathway in experimental models of AD was investigated. Here, AKT1 is linked to Alzheimer disease.